Robert Renninger's most recent trade in Athira Pharma Inc was a trade of 12,359 Common Stock done . Disclosure was reported to the exchange on June 30, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Athira Pharma Inc | Robert Renninger | SVP, Finance and Accounting | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jun 2025 | 12,359 | 112,083 | - | 0 | Common Stock | |
| Athira Pharma Inc | Robert Renninger | SVP, Finance and Accounting | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jun 2025 | 12,359 | 12,359 | - | - | Restricted Stock Units | |
| Athira Pharma Inc | Robert Renninger | SVP, Finance and Accounting | Grant, award, or other acquisition of securities at price $ 0.23 per share. | 30 Jun 2025 | 10,000 | 99,724 | - | 0.2 | 2,312 | Common Stock |
| Athira Pharma Inc | Robert Renninger | SVP, Finance and Accounting | Sale of securities on an exchange or to another person at price $ 0.29 per share. | 30 Jun 2025 | 2,897 | 109,186 | - | 0.3 | 850 | Common Stock |
| Athira Pharma Inc | Robert Renninger | SVP, Finance and Accounting | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 73,350 | 73,350 | - | - | Stock Option (Right to Buy) | |
| Athira Pharma Inc | Robert Renninger | SVP, Finance and Accounting | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 73,350 | 73,350 | - | - | Stock Option (Right to Buy) | |
| Athira Pharma Inc | Robert Renninger | SVP, Finance and Accounting | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 58,500 | 58,500 | - | - | Stock Option (Right to Buy) | |
| Athira Pharma Inc | Robert Renninger | SVP, Finance and Accounting | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 39,000 | 39,000 | - | - | Restricted Stock Units | |
| Athira Pharma Inc | Robert Renninger | VP of Finance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2024 | 12,359 | 92,605 | - | 0 | Common Stock | |
| Athira Pharma Inc | Robert Renninger | VP of Finance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2024 | 12,359 | 24,718 | - | - | Restricted Stock Units | |
| Athira Pharma Inc | Robert Renninger | VP of Finance | Grant, award, or other acquisition of securities at price $ 0.55 per share. | 31 Dec 2024 | 3,651 | 80,246 | - | 0.5 | 2,008 | Common Stock |
| Athira Pharma Inc | Robert Renninger | VP of Finance | Sale of securities on an exchange or to another person at price $ 0.56 per share. | 31 Dec 2024 | 2,881 | 89,724 | - | 0.6 | 1,619 | Common Stock |
| Athira Pharma Inc | Robert Renninger | VP of Finance | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2024 | 37,077 | 37,077 | - | - | Stock Option (Right to Buy) | |
| Athira Pharma Inc | Robert Renninger | VP of Finance | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2024 | 37,077 | 37,077 | - | - | Restricted Stock Units |